US EditionBiogen is buying up an immune drug developer for $1.8 billion
Summary by Quartz
1 Articles
1 Articles
All
Left
Center
1
Right
Biogen is buying up an immune drug developer for $1.8 billion
Biotechnology giant Biogen said on Wednesday that it is acquiring immune drug developer Human Immunology Biosciences (HI-Bio) to boost its late-stage pipeline and immunology portfolio. Biogen has agreed to a $1.15 billion upfront payment and up to $650 million in additional payments if certain milestones are met.Read more...
·United States
Read Full ArticleCoverage Details
Total News Sources1
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
